The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Open accessAbstract
Signal transducer and activator of transcription (STAT) 3 is one of the most complex regulators of transcription. Constitutive activation of STAT3 has been reported in many types of tumors and depends on mechanisms such as hyperactivation of receptors for pro-oncogenic cytokines and growth factors, loss of negative regulation, and excessive cytokine stimulation. In contrast, somatic STAT3 mutations are less frequent in cancer. Several oncogenic targets of STAT3 have been recently identified such as c-myc, c-Jun, PLK-1, Pim1/2, Bcl-2, VEGF, bFGF, and Cten, and inhibitors of STAT3 have been developed for cancer prevention and treatment. However, despite the oncogenic role of STAT3 having been widely demonstrated, an increasing amount of data indicate that STAT3 functions are multifaced and not easy to classify. In fact, the specific cellular role of STAT3 seems to be determined by the integration of multiple signals, by the oncogenic environment, and by the alternative splicing into two distinct isoforms, STAT3α and STAT3β. On the basis of these different conditions, STAT3 can act both as a potent tumor promoter or tumor suppressor factor. This implies that the therapies based on STAT3 modulators should be performed considering the pleiotropic functions of this transcription factor and tailored to the specific tumor type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–210 of 210
Tang, J., Kong, X., Banerjee, A., Muniraj, N., Pandey, V., Steiner, M., Perry, J. K., Zhu, T., Liu, D., & Lobie, P. E. (2010) · Endocrinology · doi:10.1210/en.2010-0273 · Cited by 36
Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
Murakami, T., Takigawa, N., Ninomiya, T., Ochi, N., Yasugi, M., Honda, Y., Kubo, T., Ichihara, E., Hotta, K., Tanimoto, M., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.011 · Cited by 35
Stat3-mediated alterations in lysosomal membrane protein composition
Lloyd‐Lewis, B., Krueger, C. C., Sargeant, T. J., D’Angelo, M. E., Deery, M. J., Feret, R., Howard, J. A., Lilley, K. S., & Watson, C. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001777 · Cited by 35
Liu, L., Gaboriaud‐Kolar, N., Vougogiannopoulou, K., Tian, Y., Wu, J., Wen, W. X., Skaltsounis, A., & Jove, R. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26721 · Cited by 30
HIC1 interacts with and modulates the activity of STAT3
Lin, Y.-M., Wang, C.-M., Jeng, J., Leprince, D., & Shih, H. (2013) · Cell Cycle · doi:10.4161/cc.25365 · Cited by 24
Wu, M., Wang, L., Li, F., Hu, R., Ma, J., Zhang, K., & Cheng, X. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02936-9 · Cited by 24
Identification of novel regulators of STAT3 activity
Parri, E., Kuusanmäki, H. A., van Adrichem, A. J., Kaustio, M., & Wennerberg, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230819 · Cited by 24
Zhang, L., Wang, Y., Dong, Y., Chen, Z., Eckols, T. K., Kasembeli, M. M., Tweardy, D. J., & Mitch, W. E. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00603.2019 · Cited by 24
Ge, H., Liu, H.-G., Fu, Z., & Sun, Z. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000207 · Cited by 14
Samaan, A., & Mahana, W. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.01.008 · Cited by 11
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Advances in the role of STAT3 in macrophage polarization
Xia, T., Zhang, M., Lei, W., Yang, R., Fu, S., Fan, Z., Yang, Y., & Zhang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160719 · Cited by 284
Metadata
- Authors
- Tolomeo, M., & Cascio, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-09
- Volume
- 22
- Issue
- 2
- Pages
- 603
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3119177747
- Cited by
- 318
- References
- 210
- FWCI
- 16.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.